title: Verteporfin photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia: a 12-month retrospective review.
abstract: OBJECTIVE
  To evaluate the visual outcome of patients with subfoveal choroidal neovascularization (CNV) secondary to pathologic myopia treated with verteporfin photodynamic therapy (PDT-V) and to verify the predictive role of visual and angiographic parameters.
  
  
  METHODS
  This is a retrospective, interventional, consecutive case series study of subjects with subfoveal CNV secondary to pathologic myopia. All patients received PDT-V according to VIP guidelines. A complete ophthalmologic evaluation was performed on all patients and included best-corrected visual acuity (BCVA), fundus examination, and fluorescein angiography (FA, IMAGEnet System, Topcon Corp., Japan). CNV size (mm2) was directly measured on the early phase of the angiogram using the software included with the IMAGEnet package. All checks were scheduled at 3-month intervals for a period of 1 year. A review of medical and angiographic records was performed and assessed throughout a 12-month follow-up period.
  
  
  RESULTS
  A total of 62 patients (62 eyes) were examined. Best-corrected visual acuity (BCVA) moderately decreased without reaching a statistically noticeable level throughout the followup; reduction in lesion size reached a significant level at the second checkup. A significant correlation between higher baseline BCVA and better final visual outcome was detected.
  
  
  CONCLUSIONS
  Standardized PDT-V minimizes central vision deterioration in patients with CNV secondary to pathologic myopia. Better BCVA at presentation represents a good predictive sign.
authors.affiliation: Dipartimento di Scienze per la Salute, Università degli Studi del Molise, Campobasso - Italy. ciro.costagliola@unimol.it
authors.forename: C
authors.initials: C
authors.lastname: Costagliola
authors.forename: C
authors.initials: C
authors.lastname: Campa
authors.forename: C
authors.initials: C
authors.lastname: Incorvaia
authors.forename: F
authors.initials: F
authors.lastname: Parmeggiani
authors.forename: M
authors.initials: M
authors.lastname: Menzione
authors.forename: M
authors.initials: M
authors.lastname: Della Corte
authors.forename: M
authors.initials: M
authors.lastname: Rinaldi
authors.forename: M
authors.initials: M
authors.lastname: Romano
authors.forename: F
authors.initials: F
authors.lastname: Semeraro
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography; D005584:Fovea Centralis; D006801:Humans; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications* / Q000503:physiopathology; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin